GERON CORP Proceeds from Sale of Debt Securities, Available-for-sale
GERON CORP (GERN) reported Proceeds from Sale of Debt Securities, Available-for-sale of $7.68 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2023-03-16
- GERON CORP proceeds from sale of debt securities, available-for-sale for the quarter ending 2020-12-31 was $0.00.
- GERON CORP proceeds from sale of debt securities, available-for-sale for the quarter ending 2020-09-30 was $0.00.
- GERON CORP proceeds from sale of debt securities, available-for-sale for the quarter ending 2014-12-31 was $6.04M.
- GERON CORP proceeds from sale of debt securities, available-for-sale for fiscal 2020 was $7.68M.
- GERON CORP proceeds from sale of debt securities, available-for-sale for fiscal 2015 was $4.24M, a 59.79% decline from fiscal 2014.
- GERON CORP proceeds from sale of debt securities, available-for-sale for fiscal 2014 was $10.55M.
- GERON CORP proceeds from sale of debt securities, available-for-sale for fiscal 2011 was $809.00K.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $7.68M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $7.68M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $7.68M 10-Q · filed 2021-08-16 | |||
| 2015-12-31 | $4.24M 10-K · filed 2018-03-16 | |||
| 2014-12-31 | $6.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $10.55M 10-K · filed 2017-03-01 | ||
| 2014-09-30 | $4.51M 10-Q · filed 2014-11-05 | |||
| 2011-12-31 | $809.00K 10-K · filed 2014-03-17 | |||
| 2010-12-31 | $0.00 10-K · filed 2012-03-07 | |||
| 2009-12-31 | $0.00 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |